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ART ICLE Open Ac ce s s
Mediterranean diet adherence and rate of
cerebral Aβ-amyloid accumulation: Data
from the Australian Imaging, Biomarkers
and Lifestyle Study of Ageing
Stephanie R. Rainey-Smith1,2, Yian Gu3,4, Samantha L. Gardener1,2, James D. Doecke 5,6, Victor L. Villemagne7,
Belinda M. Brown2,8, Kevin Taddei1,2, Simon M. Laws 6,9,10, Hamid R. Sohrabi 1,2,11, Michael Weinborn1,2,12,
David Ames13,14, Christopher Fowler15, S. Lance Macaulay 5, Paul Maruff15,16, Colin L. Masters15, Olivier Salvado5,
Christopher C. Rowe7, Nikolaos Scarmeas3,4,17,18 and Ralph N. Martins1,2,11,19
ABSTRACT
Accumulating research has linked Mediterranean diet (MeDi) adherence with slower cognitive decline and reduced
Alzheimer’s disease (AD) risk. However, no study to-date has examined the relationship between MeDi adherence and
accumulation of cerebral Aβ-amyloid (Aβ; a pathological hallmark of AD) in older adults. Cognitively normal healthy
control participants of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Ageing completed the Cancer
Council of Victoria Food Frequency Questionnaire at baseline, which was used to construct a MeDi score for each
participant (score range 0–9; higher score indicating higher adherence). Cerebral Aβ load was quantified by Pittsburgh
Compound B positron emission tomography at baseline, 18 and 36 months: Only individuals categorised as “Aβ
accumulators”, and thus considered to be on the AD pathway, were included in the analysis (N= 77). The relationship
between MeDi adherence, MeDi components, and change in cerebral Aβ load (baseline to 36 months) was evaluated
using Generalised Linear Modelling, accounting for age, gender, education, Apolipoprotein E ε4 allele status, body mass
index and total energy intake. Higher MeDi score was associated with less Aβ accumulation in our cohort (β=−0.01 ±
0.004, p= 0.0070). Of the individual MeDi score components, a high intake of fruit was associated with less accumulation
of Aβ (β=−0.04 ± 0.01, p= 0.00036). Our results suggest MeDi adherence is associated with reduced cerebral AD
pathology accumulation over time. When our results are considered collectively with previous data linking the MeDi to
slower cognitive decline, it is apparent that MeDi adherence warrants further investigation in the quest to delay AD onset.
Introduction
Currently, no cure for Alzheimer’s disease (AD) exists, it
is therefore essential that effective and broadly applicable
approaches to prevent or delay disease onset are
developed. Accumulating data suggests that diet repre-
sents one such strategy accessible to all.
The Mediterranean diet (MeDi), has been widely
recognised as a healthy eating model due to its correlation
with low morbidity and mortality for many chronic dis-
eases, including cardiovascular disease and diabetes1,2,
which are themselves risk factors for AD3,4. Indeed,
accumulating research, including our own, has linked
MeDi adherence with slower cognitive decline and
reduced risk of AD5–7. Precisely how the MeDi confers
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such cognitive benefit remains to be determined; brain
imaging studies likely offer some insight. Relatively few
studies however, have examined the relationship of MeDi
adherence to AD-related neuroimaging outcome mea-
sures. Higher adherence to MeDi has been associated with
greater cortical thickness8, whilst similarly, lower MeDi
adherence has been shown to be predictive of increased
total brain atrophy9. To-date, only one study has directly
examined the relationship between MeDi adherence and
cerebral Aβ-amyloid (Aβ) load (a pathological hallmark of
AD), with the authors reporting reduced cerebral Aβ load
cross-sectionally among individuals with high MeDi
adherence10.
There is a critical need to explore the relationship
between MeDi and rates of cerebral Aβ accumulation
using longitudinal data collected from a well-
characterised ageing cohort. Consequently, the aim of
the current study was to assess the relationship between
MeDi adherence, MeDi components, and Pittsburgh
Compound B positron emission tomography (PiB-PET)
determined cerebral Aβ burden longitudinally, in cogni-
tively normal healthy control participants of the Aus-
tralian Imaging, Biomarkers and Lifestyle (AIBL) Study of
Ageing, who were categorised as “Aβ accumulators”, and
thus considered to be on the AD pathway. We hypothe-
sised that higher MeDi adherence would be associated
with less accumulation of cerebral Aβ over time.
Methods
Participants
This report describes data from 77 participants taken
from the AIBL Study of Ageing11 who were classified as
healthy controls (cognitively ‘normal’) and completed the
Cancer Council of Victoria Food Frequency Ques-
tionnaire (CCVFFQ) at baseline, and who were cate-
gorised as “Aβ accumulators”12 as determined by PiB-PET
imaging undertaken to assess cerebral Aβ levels at base-
line, 18 and 36-month follow-up assessments. Baseline
assessments commenced in October 2006, and 36-month
follow-up assessments were completed in October 2011.
All volunteers were aged 60 years and above at baseline,
and further details regarding recruitment, assessment,
inclusion, and exclusion criteria are described in Ellis
et al11. The AIBL Study is approved by the institutional
ethics committees of Austin Health, St Vincent’s Health,
Hollywood Private Hospital and Edith Cowan Uni-
versity11. Written informed consent was obtained from
each participant prior to undertaking any procedures
related to the study.
Food frequency questionnaires
The CCVFFQ is a 74 single item, semi-quantitative,
machine-scannable FFQ, which is optically scanned to
provide grams per day of food and nutrient intake. The
CCVFFQ has been validated relative to seven-day weighed
food records in pre-menopausal women13,14. The com-
pleted questionnaires are analysed by the Cancer Council
in Carlton, Victoria. The food composition data used to
calculate daily nutrient intake originates from the Nutri-
ent Tables for use in Australia 1995 NUTTAB95;15 the
CCVFFQ takes approximately ten minutes to complete
and assesses usual daily intake over the preceding
12 months. Participants completed the CCVFFQ when
they attended the research centre for assessment.
The CCVFFQ data were used to construct a MeDi score
for each participant using the most commonly described
method;16 however, cohort sex-specific medians rather
than population sex-specific medians were used. A value
of 1 was assigned for; (i) each beneficial component
(fruits, vegetables, legumes, cereals and fish) if caloric-
adjusted consumption was at or above the cohort sex-
specific median; (ii) each detrimental component (meat
and dairy) if caloric-adjusted consumption was below the
sex-specific median; and (iii) a ratio of monounsaturated
to saturated fats at or above the median. Individuals were
assigned a value of 1 for mild-to-moderate alcohol con-
sumption (>5 to <25 g per day for females and >10 to
<50 g per day for males). A MeDi score was subsequently
generated for each participant by summing the scores for
each category; MeDi score ranged from 0–9, with higher
score indicating greater adherence5.
Aβ-amyloid imaging
Cerebral Aβ load was assessed at baseline, 18 and 36-
month follow-up using 11C-Pittsburgh Compound B
(PiB) positron emission tomography (PET). PET metho-
dology has previously been described in detail12. Briefly, a
30-minute acquisition was performed 40min post-
injection of PiB. For semi-quantitative analysis, a volume
of interest template was applied to the summed and
spatially normalised PET images in order to calculate a
standardised uptake value (SUV). Images were then scaled
to the SUV of the cerebellar cortex (reference region) to
generate a tissue ratio termed SUV ratio (SUVR). Global
SUVR was calculated using the mean SUVR in the frontal,
superior parietal, lateral temporal, occipital and anterior
and posterior cingulate regions. Only individuals cate-
gorised as “Aβ accumulators” were included in the cur-
rent study; i.e., participants with an already high Aβ
burden (SUVR ≥1·4) in the brain at baseline, or those who,
despite having a low Aβ burden (SUVR <1·4) in the brain,
presented with rates of Aβ accumulation higher than 0
over 36 months12.
Apolipoprotein E genotyping
Fasting blood samples were obtained using standard
venepuncture of the antecubital vein and collected into
EDTA tubes containing Prostaglandin E1 (PGE; Sapphire
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Bioscience, NSW, Australia, 33·3 ng/ml) to prevent pla-
telet activation. Extraction of DNA from 5ml of whole
blood was undertaken using QIAamp DNA Blood Maxi
Kits (Qiagen, Hilden, Germany) as per the manufacturer’s
instructions. Specific TaqMan® (Thermo Fisher Scientific,
Waltham, MA, USA) genotyping assays were used for
ascertaining Apolipoprotein E (APOE) genotype (rs7412,
assay ID: C____904973_10; rs429358, assay ID:
C___3084793_20), which were performed on a Quant-
Studio 12 K Flex™ Real-Time-PCR system (Thermo Fisher
Scientific, Waltham, MA, USA) using the TaqMan®
GTXpress™ Master Mix (Thermo Fisher Scientific, Wal-
tham, MA, USA).
Statistical analysis
Means, standard deviations and percentages are pro-
vided for the demographics of the entire cohort (Table 1).
Demographic group differences were evaluated using
independent sample t-tests for continuous variables and
chi-square (χ2) analysis for categorical variables. MeDi
score components were transformed initially to remove
those outliers that were obviously erroneous data, with
the erroneous data replaced with median values.
Change in Aβ over 36 months was represented using
the beta coefficients from a robust linear model, whereby
individual SUVR values were modelled against time
(baseline, 18 and 36 months). Two separate modelling
(Generalised Linear Model, GLM) strategies considered;
(1) assessment of the total MeDi score alone (adjusted for
covariates, with and without APOE ε4 allele status
interaction), and (2) assessment of all the individual
components of the total MeDi score (intake of meat, fish,
vegetables, cereals, legumes, dairy, fruit, alcohol per day
and the ratio of monounsaturated fatty acids to saturated
fatty acids; including covariates; excluding total MeDi
score) using a stepwise linear model. The stepAIC (Akaike
information criterion) function was used to identify the
best model, before reducing to the strongest components.
Covariate factors included age, gender, education (2
groups; ≤12 years/>12 years), APOE ε4 allele status (2
groups; absence of ε4 allele/ presence of either one or two
ε4 alleles) and body mass index (BMI). From the final
models, p-values less than 0.05 were classed statistically
significant. All statistical analyses were performed using R
version 3.3.2 (2016-10-31; R Foundation for Statistical
Computing, Vienna, Austria). Visualisation of the MeDi
score with change in SUVR was investigated using tradi-
tional tertile transformation.
Results
The cohort comprised 77 cognitively normal healthy
control “Aβ accumulator” participants (51% male) with an
average age of 71.1 ± 7.1 years. Forty-two per cent were
carriers of at least one APOE ε4 allele (the most common
genetic risk factor for AD) and more than half had 13 or
more years of education. The median MeDi score of the
cohort was 4 (interquartile range 2) and 65% of partici-
pants had an SUVR less than 1.4 at baseline (Table 1).
When assessing the effect of MeDi score on the change
in Aβ over 36 months, adjusting for age, gender and
APOE ε4 allele status, an inverse relationship was seen,
with increasing MeDi score associated with decreasing
SUVR (β=−0.01 ± 0.004, p= 0.0070). Given the average
accumulation rate of Aβ in this cohort was 0.05 SUVR
units/year, altering the diet of an individual to increase
MeDi score by one point would result in an approximate
20% decrease in Aβ accumulation over a one year period,
and up to a 60% decrease in accumulation over three
years.
When evaluating which individual components of the
total MeDi score were contributing most strongly to the
decreased rate of Aβ accumulation, the optimal model
from the stepwise regression (based on the AIC; including
all covariates and MeDi score components; excluding
total MeDi score) included age (β= 0.002 ± 0.0008,
p= 0.0083), APOE ε4 allele status (β= 0.03 ± 0.01,
p= 0.0095), and the intakes of fruit (β= -0.04 ± 0.01,
p= 0.00085), meat (β=−0.02 ± 0.01, p= 0.057), cereals
(β=−0.02 ± 0.01, p= 0.13) and dairy (β= 0.02 ± 0.01,
p= 0.13). Reducing this to a minimalistic model given the
sample size, the final model included age (β= 0.002 ±
0.0008, p= 0.020), APOE ε4 allele status (β= 0.03 ± 0.01,
p= 0.021) and fruit intake (β=−0.04 ± 0.01, p=
0.00036). Covariates not included in the final model did
Table 1 Descriptive statistics for the cognitively normal
healthy control “Aβ accumulator” cohort who completed
the CCVFFQ at baseline, and underwent PiB-PET imaging
to assess cerebral Aβ levels at baseline, 18 and 36-month
follow-up assessments
Total sample (N= 77)
Gender male, N (%) 39 (51)
Mean age, years (SD) 71.1 (7.1)
APOE ε4 carriage, N (%) 32 (42)
Mean BMI at baseline (SD)a 26.2 (3.2)
Years of education >12 years, N (%) 44 (57)
Mean MMSE at baseline (SD) 29 (2)
Median MeDi score (IQR) 4 (2)
SUVR < 1.4 at baseline, N (%) 50 (65)
Aβ Aβ-amyloid; APOE apolipoprotein E, BMI body mass index, CCVFFQ Cancer
Council of Victoria Food Frequency Questionnaire, IQR interquartile range, MeDi
Mediterranean diet, MMSE Mini-Mental State Examination, PiB-PET 11C-
Pittsburgh Compound B positron emission tomography, SD standard deviation,
SUVR standardised uptake value ratio
aBody mass index is calculated as weight in kilograms divided by height in
meters squared
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not contribute towards variance in the outcome, and were
removed via the stepAIC procedure. Complete results
from the GLM are presented in Table 2.
No significant interaction between MeDi score and
APOE ε4 allele status was observed for the change in
SUVR via the GLM (β= 0.007 ± 0.008, p= 0.37). The beta
coefficient and resultant p-value for MeDi score however
were moderately stronger (β=−0.012 ± 0.004, p=
0.0068), while the beta coefficient and resultant p-value
for APOE ε4 allele status was abrogated (β= 0.002 ± 0.04,
p= 0.96; Table 2).
Graphical representation of the change in SUVR per
year between MeDi score tertiles and ‘high’ / ‘low’ fruit
intake demonstrates higher overall rates of Aβ
accumulation in those participants with ‘low’ MeDi
adherence (tertile 1) and with ‘low’ fruit intake (Fig. 1);
there were however, still four participants in the ‘high’
MeDi adherence tertile (tertile 3) with relatively high Aβ
accumulation rates. Further investigation of these four
participants found all were APOE ε4 allele carriers.
Discussion
The aim of the current study was to assess the rela-
tionship between MeDi adherence, intake of individual
MeDi components, and change in cerebral Aβ burden
over 36 months, in cognitively normal healthy control
participants of the AIBL Study who were categorised as
“Aβ accumulators”, and thus considered to be on the AD
pathway. Increasing MeDi adherence was associated with
less Aβ accumulation in our cohort (adjusted for con-
founders), with fruit intake the MeDi component see-
mingly conferring the greatest benefit. These data suggest
that MeDi adherence is beneficial for maintaining brain
health in Australian older adults, by slowing accumulation
of cerebral AD pathology.
The health benefits of the MeDi are well-established,
with a plethora of studies linking adherence to this dietary
pattern to low morbidity and mortality for numerous
chronic diseases, including diabetes, cardiovascular and
cerebrovascular disease (e.g., refs 1,2,17.); conditions which
are themselves risk factors for AD3,4,18. The direct rela-
tionship between MeDi adherence and decreased AD risk
has also been investigated, with higher MeDi adherence
associated with lower incidence of mild cognitive
impairment (MCI) and AD7,19, as well as with slower
cognitive decline among cognitively normal older adults5.
Furthermore, the results of a recently completed, four
year, randomised clinical trial (RCT), revealed that cog-
nitively normal participants adhering to a MeDi, supple-
mented with either extra-virgin olive oil or mixed nuts,
demonstrated cognitive improvement compared to the
control group who experienced age-related cognitive
decline20.
Few studies however, have examined the relationship of
MeDi adherence to AD-related neuroimaging outcome
measures. Investigations utilising magnetic resonance
imaging (MRI) have found higher MeDi adherence to be
associated with greater cortical thickness8, whilst similarly,
lower MeDi adherence has been shown to be predictive of
total brain atrophy over three years9. A recent cross-
sectional study of individuals with MCI or subjective
memory impairment (N= 44) reported a relationship
between greater frequency of following a Mediterranean-
type diet and less brain Aβ/tau burden as assessed by 2-(1-
(6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl)ethy-
lidene)malononitrile (18F-FDDNP); a pan-amyloid PET
tracer that binds to both Aβ plaques and tau deposits.
Unfortunately, however, the lack of selectivity of the tracer
Table 2 GLM coefficients: MeDi score to predict change in
SUVR over 36 months
Model / Variable β coefficient SE t-value p-value
Initial model including total MeDi score (without MeDi score components):
(Intercept) −0.02905 0.06602 −0.44006 0.66120
MeDi Score −0.01015 0.00366 −2.77308 0.00704
APOE ε4 allele status 0.03134 0.01228 2.55229 0.01279
Age 0.00164 0.00086 1.90979 0.06009
Second model including MeDi score components (without total MeDi score):
(Intercept) −0.08644 0.06313 −1.36934 0.17527
Fruit intake (0/1) −0.03802 0.01091 −3.48617 0.00085
Age 0.00225 0.00083 2.71501 0.00834
APOE ε4 allele status 0.03061 0.01147 2.66877 0.00945
Meat intake (0/1) −0.02215 0.01144 −1.93659 0.05683
Cereals intake (0/1) −0.01758 0.01150 −1.52890 0.13080
Dairy intake (0/1) 0.01705 0.01118 1.52563 0.13161
Second model (reduced)
(Intercept) −0.07342 0.06033 −1.217 0.22760
Fruit intake (0/1) −0.04143 0.01107 −3.744 0.00036
Age 0.00196 0.00082 2.385 0.01967
APOE ε4 allele status 0.02749 0.01170 2.350 0.02148
Interaction model (Total MeDi score)
(Intercept) −0.03027 0.06612 −0.458 0.64850
MeDi score −0.01245 0.00447 −2.786 0.00681
Age 0.00178 0.00087 2.037 0.04532
APOE ε4 allele status 0.00157 0.03526 0.045 0.96453
MeDi score * APOE ε4
allele status
0.00701 0.00780 0.901 0.37061
All beta (β) coefficients (± SE) from the GLM are shown. Bold indicates statistical
significance (p < 0.05)
APOE apolipoprotein E, GLM generalised linear model, MeDi Mediterranean diet,
SE standard error, SUVR standardised uptake value ratio
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makes it impossible to determine whether the diet was
associated with Aβ, tau, or a combination of both21. To-
date, only one study has specifically examined the rela-
tionship between MeDi adherence and cerebral Aβ load.
Consistent with our findings, the authors reported reduced
cerebral Aβ load among individuals with high MeDi
adherence10. However, this study was cross-sectional in
design and utilised a relatively small cohort (N= 45) of
cognitively normal adults: Factors, the authors themselves
described as limitations, which are addressed in the cur-
rent study, being both longitudinal in design, and utilising
data collected from a larger cohort of cognitively normal
older adults (N= 77).
In our cohort, each one point MeDi score increase was
associated with a 0.01 SUVR unit decrease in the accu-
mulation of Aβ over three years; i.e., an individual who
increased their MeDi adherence from 0 to 9 could
potentially demonstrate a 0.09 SUVR unit decrease in the
accumulation of Aβ over three years compared to a 0.01-
unit decrease if they increased their MeDi adherence from
0 to 1. Consistent with estimates of brain Aβ accumula-
tion from Villemagne et al.12, the average annual increase
in brain Aβ in our cohort of known cognitively healthy
“Aβ accumulators” was 0.05 SUVR units, which over
36 months would equate to an increase of 0.15. Thus, our
findings suggest that adherence to the MeDi could
potentially reduce this accumulation of Aβ by up to 60%
over three years; thereby presenting a feasible strategy to
slow the accumulation of cerebral AD pathology.
How MeDi adherence might exert such beneficial
effects remains to be determined. Specifically, it cannot be
determined from the current study whether MeDi
adherence is associated with reduced Aβ production and
deposition, increased Aβ clearance, or a combination of
both. Indeed, the MeDi is an abundant source of vitamin
A (both preformed vitamin A: retinol and its esterified
form, retinyl ester, found in foods from animal sources,
including dairy products, fish, and meat; and pro-vitamin
A carotenoids, found in plant pigments), which has been
shown to demonstrate anti-oligomerization effects on Aβ
in vitro22. Further, dietary deficiency of vitamin A
increases cerebral Aβ deposition in animal models23. The
monounsaturated omega-9 fatty acid, oleic acid comprises
the majority of olive oil, which is consumed readily as part
of the MeDi. Oleic acid has been shown to inhibit activity
of the amyloidogenic pathway enzyme Beta-secretase 1
(BACE1) in vitro24, and to ameliorate amyloidosis in a
cellular model of AD25. MeDi adherence may also posi-
tively modulate levels of Aβ-degrading proteases. For
example, MeDi adherence has been associated with
reduced levels of fasting insulin 26, which consequently
increases levels of ‘free’ insulin-degrading enzyme; a well-
established Aβ-degrading protease27. The MeDi has also
been linked to beneficial effects for multiple determinants
of cardiovascular disease risk, including decreased low
density lipoprotein cholesterol and increased high density
lipoprotein (HDL) cholesterol (see ref. 28 for an overview
of associated RCTs). HDL maintains Aβ solubility within
plasma and cerebrospinal fluid29, and increasing levels of
HDL has been postulated to enhance lipoprotein
receptor-related protein clearance of Aβ (e.g ref. 30).
Indeed, one might hypothesise that the most plausible
explanation for the observed association between MeDi
adherence and reduced Aβ accumulation in the current
study is a complex milieu of beneficial effects rather than
a single consummate anti-Aβ mechanism.
Fig. 1 Plots demonstrate the relationship between MeDi score in tertiles and median change in SUVR per year (left), and fruit intake and
median change in SUVR per year (right). MeDi score tertile 1= lowest MeDi adherence; 3= highest MeDi adherence. Fruit intake was categorised
as ‘low’ or ‘high’ using cohort sex-specific caloric-adjusted medians as the cut-off. Upper horizontal line shows the third quartile above the median
change in SUVR per year, middle horizontal line is the median change, and lower horizontal line shows the first quartile below the median change.
MeDi Mediterranean diet, SUVR standardised uptake value ratio
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Our results suggest that fruit intake is an important
element of MeDi adherence which confers benefit in our
cohort, specifically; higher intake was associated with less
accumulation of Aβ. Whilst the potential mechanism is
unclear, we speculate that it may relate to polyphenolic
content. For example, the citrus flavonoid nobiletin has
been shown to decrease Aβ burden in the brains of AD
mouse models31, whilst (−)-epicatechin (abundant in
multiple fruits) has been associated both with reduced Aβ
pathology in a double transgenic mouse model of AD, and
potent inhibition of amyloidogenic processing in vitro32.
The high concentration of vitamin C in fruits consumed
as part of the MeDi (e.g. oranges, grapefruit and straw-
berries) may also contribute to slowing accumulation of
cerebral AD pathology. Vitamin C supplementation has
been shown to reduce amyloid plaque burden in the brain
of a transgenic mouse model of AD which had been
genetically engineered to be unable to synthesize its own
vitamin C (important as the ability of rodents to synthe-
size vitamin C with no reliance on dietary supply has
hampered previous investigations)33. Moreover, vitamin C
has been shown to inhibit amyloid fibril formation
in vitro34.
There are limitations to our report that require con-
sideration; this is an observational study, therefore we can
draw no conclusions regarding causality. Further, the
CCVFFQ utilised in this study relies on participants’
estimations of food intake over the previous year; this is a
common limitation of studies of diet and can potentially
lead to misclassification of dietary intake due to limited
accuracy. This is particularly important with regards to
cognitively impaired participants, thus, to circumvent this
limitation, only cognitively normal older adults were
included in the current analysis. Nevertheless, we recog-
nise that ideally, a targeted intervention substantiated
with biomarker measures for actual consumption/uptake
would be utilised to both determine causality and to evade
the limitations of self-report.
Many aspects of our study, however, provide confidence
in our findings. We have utilised a well-characterised
cohort thereby increasing the internal validity of our
results. We have taken a rigorous approach to statistical
analysis. The dietary data were collected using an
instrument previously validated in epidemiological stu-
dies13,14. Moreover, our findings are consistent with many
published studies which describe the benefits of MeDi
adherence in the context of both AD risk and severity of
cerebral pathology (e.g., refs 6,7,9,10,17).
This is the first study to assess the relationship between
MeDi adherence and change in cerebral Aβ burden over
time in older adults. In summary, the results of this study
highlight the potentially beneficial impact of MeDi
adherence on slowing rates of cerebral Aβ accumulation
in cognitively unimpaired older adults. Whilst validation
of our findings is required using a targeted intervention,
when our results are considered collectively with previous
data linking the MeDi to improved cognition, it appears
that MeDi adherence warrants further investigation in the
quest to delay or ideally prevent AD onset.
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